Ongoing discussions with multiple large Pharma's5 Nov 2025 05:10
Hemogenyx Pharmaceuticals' CEO, Dr. Vladislav Sandler, has confirmed the company is in ongoing discussions with multiple large pharmaceutical companies regarding potential partnerships, joint ventures, or a possible acquisition for its lead CAR-T therapy, HG-CT-1.
The specific identity of these "big pharma" companies and the details of the negotiations are not publicly disclosed due to confidentiality agreements (NDAs).
Key Details:
β
οΈ .Ongoing Discussions: Dr. Sandler has explicitly stated that he is in discussions with "Pharmaceutical companies" that means more than one company is in talks after understanding & seen the data. Right β
οΈ
β
οΈ Confidentiality: The nature of these talks is highly confidential, and the "first time" retail investors are likely to hear concrete news will be through an official regulatory news announcement (RNS) if a deal is reached.β
οΈ
Potential Deal Structure: Discussions could lead to various outcomes, including:
.A joint venture (JV). β
οΈ
.Upfront payments and milestone payments. β
οΈ
.A full acquisition or buy-out of the company or specific assets.β
οΈ
Driving Factors: The discussions are likely spurred by positive, early safety and efficacy signals from the ongoing Phase I clinical trial of HG-CT-1 for relapsed/refractory Acute Myeloid Leukemia (R/R AML).π
Recent Milestones: Recent developments, such as the clearance for pediatric enrollment and a manufacturing partnership with Made Scientific, are seen as positive steps that make the company a more attractive partner for major pharmaceutical firms.π
Timeline: While a timeline for a deal is not confirmed, many of us shareholders are speculating that a positive RNS could be forthcoming once more clinical data is available, particularly from the higher-dose adult cohort or the first pediatric patient which is very soon now...π
As soon as we get the data from P4 and the 1st pediatric patient the better the shareprice will be I mean it will fly like a rocket and the price tag reflect the results and we the the shareholders will be rewarded accordingly. β
οΈ
So just watch this space it's been 1 week since Vlad's video was released, I expect some major progress has been made as he now knows the science works very well from the successful results already observed in 3 patients at a lower dose level.
With over Β£2 million in the bank now so, no need for any more funds for now and if Hemo needs any funds going forward it will be in a non dilution format. The model and road map is clearly clear as day now, what more can an investor ask for.
Low operating costs model now β
οΈ
Money in the bank β
οΈ
The science works β
οΈ
Bargain shareprice now under 2p = big returns π°
Awaiting the big go ahead P4, 1st pediatric patient treated, JV β
οΈ
I expect a blockbuster RNS to land very soon and the pulled back spring coiled shareprice will pop blowing the doors off and the shareprice